Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,519 JPY | +1.67% | +2.64% | +6.90% |
Sales 2024 * | 35.22B 227M | Sales 2025 * | 38.94B 251M | Capitalization | 134B 860M |
---|---|---|---|---|---|
Net income 2024 * | 951M 6.12M | Net income 2025 * | 3.47B 22.33M | EV / Sales 2024 * | 3.49 x |
Net cash position 2024 * | 10.81B 69.57M | Net cash position 2025 * | 12.21B 78.55M | EV / Sales 2025 * | 3.12 x |
P/E ratio 2024 * |
66.7
x | P/E ratio 2025 * |
26.3
x | Employees | 350 |
Yield 2024 * |
-
| Yield 2025 * |
0.05% | Free-Float | 90.37% |
Latest transcript on Nxera Pharma Co., Ltd.
1 day | +1.67% | ||
1 week | +2.64% | ||
Current month | -8.60% | ||
1 month | -7.26% | ||
3 months | +5.19% | ||
6 months | +13.70% | ||
Current year | +6.90% |
Managers | Title | Age | Since |
---|---|---|---|
Chris Cargill
CEO | Chief Executive Officer | 40 | 17-09-19 |
Shinichi Tamura
FOU | Founder | 74 | 90-06-21 |
Director of Finance/CFO | - | 22-03-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shinichi Tamura
FOU | Founder | 74 | 90-06-21 |
Noriaki Nagai
BRD | Director/Board Member | 66 | 19-03-26 |
Rolf Soderstrom
BRD | Director/Board Member | 58 | 20-03-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.92% | 24 M€ | -15.89% | ||
1.17% | 16 M€ | -5.09% | ||
0.55% | 15 M€ | +11.75% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 1,519 | +1.67% | 644 100 |
24-05-01 | 1,494 | +1.77% | 831,100 |
24-04-30 | 1,468 | +0.69% | 772,100 |
24-04-26 | 1,458 | -2.47% | 3,093,200 |
24-04-25 | 1,495 | -0.86% | 731,300 |
Delayed Quote Japan Exchange, May 02, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.90% | 848M | |
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-16.48% | 31.47B | |
+54.94% | 25.24B | |
-13.58% | 15.82B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.14% | 8.84B | |
-1.87% | 7.93B |
- Stock Market
- Equities
- 4565 Stock